Nexien BioPharma, Inc (OTC: NXEN) Developing a cannabinoid-based drug pipeline.

November 14, 2018 admin CEO Interview, Healthcare Comments Off on Nexien BioPharma, Inc (OTC: NXEN) Developing a cannabinoid-based drug pipeline.

 

 

 

 

 

 

 

 

 

Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company's cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.

This content is available to members only.

If you are an existing member, please LOGIN

Not a member? Sign up for a FREE trial account now ($49 per month value), and get immediate access.

Register New Account

Free Membership

.

Institutional / team access subscriptions, contact Melissa Walters 212-871-2057 ext 2
subscribe@wallstreetreporter.com.




Related Articles

Newsmakers

Yield Growth (OTC: BOSQF) Announces USA Luxury and Wellness Retailers to Carry Urban Juve Hemp Products

May 1, 2019 admin Newsmakers Comments Off on Yield Growth (OTC: BOSQF) Announces USA Luxury and Wellness Retailers to Carry Urban Juve Hemp Products

VANCOUVER, British Columbia, May 01, 2019 — The Yield Growth Corp. (CSE:BOSS) (OTC:BOSQF) (Frankfurt: YG3) subsidiary Urban Juve announces new U.S.A. retail contracts with luxury spa, wellness and specialty shops to sell its extensive, unisex range of […]

Add to my social media sites
SubscribeDiggdel.icio.usFacebookRedditStumbleUponTechnorati
CEO Interview

Tilray Inc, (NASDAQ: TLRY) “Global Cannabis Player” Interview with CEO Brendan Kennedy

September 20, 2018 admin CEO Interview, Consumer Comments Off on Tilray Inc, (NASDAQ: TLRY) “Global Cannabis Player” Interview with CEO Brendan Kennedy

Tilray Inc, (NASDAQ: TLRY) “Global Cannabis Player” Interview with CEO Brendan Kennedy Kennedy, discusses the medical cannabis market and expectation that more countries will be legalizing cannabis for recreational use over next 12-24 months. Add […]

Add to my social media sites
SubscribeDiggdel.icio.usFacebookRedditStumbleUponTechnorati
Healthcare

CytoDyn (OTC: CYDY) to Present New Data from Study of Investigational HIV Therapy Leronlimab (PRO 140), a Long-Acting, Single-Agent Maintenance Therapy at CROI 2019

February 28, 2019 admin Healthcare, Newsmakers Comments Off on CytoDyn (OTC: CYDY) to Present New Data from Study of Investigational HIV Therapy Leronlimab (PRO 140), a Long-Acting, Single-Agent Maintenance Therapy at CROI 2019

VANCOUVER, Washington, Feb. 27, 2019 — CytoDyn Inc. (OTC.QB: CYDY), a late stage biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that data from its study of leronlimab […]

Add to my social media sites
SubscribeDiggdel.icio.usFacebookRedditStumbleUponTechnorati